News-Medical.Net June 13, 2022
A team of researchers from National University of Singapore (NUS), in collaboration with clinicians from the National University Cancer Institute, Singapore (NCIS) which is part of the National University Health System (NUHS), has reported promising results in using CURATE.AI, an artificial intelligence (AI) tool that identifies and better allows clinicians to make optimal and personalized doses of chemotherapy for patients.
Based on a pilot clinical trial – called PRECISE.CURATE – involving 10 patients in Singapore who were diagnosed with advanced solid tumors and predominantly metastatic colorectal cancers, clinicians accepted close to 97% of doses recommended by CURATE.AI, with some patients receiving optimal doses that were approximately 20% lower on average. These early outcomes are a promising step forward for the...
Today's Sponsors
Today's Sponsor